Still Long, Hard to be believe for 2018 01:11 PM EST, 01/11/2018 (MT Newswires) -- In a research update to clients Beacon Securities analyst Doug Cooper maintained his Buy rating and one-year price target of $10.00 on ProMetic Life Sciences, reports Cantech Letter.
The analyst expects ProMetic will deliver on various milestones, including BLA filing for IVIG with Health Canada, commencement of three-armed, placebo-controlled trial for IPF with interim results expected after 26 weeks, and an improvement in its balance sheet.
He is anticipating ProMetic will generate EBITDA of negative $93.8-million on revenue of $37.5-million in fiscal 2017.
GLTA, Cheers...